Skip to main content
SpringerLink
Log in

New Trials

  • Chapter
Treatment of Peritoneal Surface Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 884 Accesses

Abstract

Primary or secondary peritoneal surface involvement represents an important occurrence in the history of patients with gastrointestinal and gynecological tumors, representing a clinical entity grouped under the name of peritoneal surface malignancies (PSM). Patient life expectancy and quality of life (QoL) are very poor when the disease had reached this phase. In the past, oncologists considered peritoneal carcinosis (PC) as a distant metastasis and therefore as an incurable intra-abdominal disease. Definitely, notwithstanding the advances in systemic chemotherapy regimens, the effects on PC are still limited, probably because of the peritoneal-plasma barrier, which prevents effective drug delivery from the systemic circulation into the peritoneal cavity [1–3]. However, novel therapeutic approaches have been attempted for patients with isolated peritoneal metastases of PSM. Indeed, disease is often restricted to the peritoneal cavity without extra-abdominal involvement, and therefore, it is possible to consider PC as a locoregional disease, and a locoregional approach is thus reasonable for treating these malignancies in humans [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Van der Speeten K, Stuart OA, Sugarbaker PH (2009) Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discover Technol 6:72–81

    Article  Google Scholar 

  2. Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53–63

    Article  CAS  PubMed  Google Scholar 

  3. Montori G, Coccolini F, Ceresoli M et al (2014) The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol 2014:912418

    PubMed Central  PubMed  Google Scholar 

  4. Chua TC, Liauw W, Saxena A et al (2011) Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg 201:149–156

    Article  PubMed  Google Scholar 

  5. Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260

    CAS  PubMed  Google Scholar 

  6. Dedrick RL (1986) Interspecies scaling of regional drug delivery. J Pharmacol Sci 75:1047–1052

    Article  CAS  Google Scholar 

  7. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sommariva A, Pilati P, Rossi CR (2012) Cyto-reductive Surgery combined with Hyperthermic Intra-Peritoneal Chemotherapy for Peritoneal Surface Malignancies: Current treatment and results. Cancer Treat Rev 38:258–268

    Article  PubMed  Google Scholar 

  9. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    CAS  PubMed  Google Scholar 

  10. Rietbroek RC, van de Vaart PJ, Haveman J et al (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123:6–12

    Article  CAS  PubMed  Google Scholar 

  11. Glehen O, Passot G, Villeneuve L et al (2012) GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14:183

    Article  Google Scholar 

  12. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  13. http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/linee+guida/1%2C333% 2C1%2C

    Google Scholar 

  14. Coccolini F, Gheza F, Lotti M et al (2013) Peritoneal Carcinomatosis. World JGastroenterol 19:6979–6994

    Article  CAS  Google Scholar 

  15. Heintz APM, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:S161–192

    Article  Google Scholar 

  16. Leitao MM Jr, Chi DS (2009) Surgical Management of Recurrent Ovarian Cancer. Semin Oncol 36:106–111

    Article  PubMed  Google Scholar 

  17. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265–274

    Article  PubMed  Google Scholar 

  18. Al Rawahi T, Lopes AD, Bristow RE et al Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2:CD008765. doi: 10.1002/14651858

    Google Scholar 

  19. Waddell T, Verheij M, Allum W et al (2013) Gastric cancer : ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann of Oncol 24:vi57–vi63

    Article  Google Scholar 

  20. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  21. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatinplus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  CAS  PubMed  Google Scholar 

  22. Yonemura Y, Bando E, Kawamura T et al (2007) Cytoreduction and intraperitoneal chemotherapy for carcinomatosis from gastric cancer. Cancer Treat Res 134:357–373

    CAS  PubMed  Google Scholar 

  23. Coccolini F, Cotte E, Glehen O et al (2014) Intraperitoneal chemotherapy in advanced gastric cancer: Meta-analysis if randomized trials. Eur J Surg Oncol 40:12–26

    Article  CAS  PubMed  Google Scholar 

  24. Yonemura Y, De Aretxabala X, Fujimura T et al (2001) Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer : final results of a randomized controlled study. Hepatogastroenterology 48:1776–1782

    CAS  PubMed  Google Scholar 

  25. Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreducion and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  26. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosi treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients in a multicentric French study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  27. Deraco M, Kusamura S, Virzì S et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multiinstitutional phase-II trial. Gynecol Oncol 122:215–220

    Article  PubMed  Google Scholar 

  28. Sugarbaker PH (1996) Peritoneal Carcinomatosis: Principles of Management. Kluwer Academic, Boston, USA

    Google Scholar 

  29. Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2–21

    Google Scholar 

  30. http://www.clinicaltrials.gov/ct2/show/ NCT01091636

    Google Scholar 

  31. http://www.clinicaltrials.gov/ct2/show/NCT01709487

    Google Scholar 

  32. http://www.clinicaltrials.gov/ct2/show/NCT01628380

    Google Scholar 

  33. Di Giorgio A, Naticchioni E, Biacchi D et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hypertermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–325

    Article  PubMed  Google Scholar 

  34. Passot G, Bakrin N, Roux AS et al (2014) Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: A prospective study of 216 patients. EJSO 40:529–535

    Article  CAS  PubMed  Google Scholar 

  35. http://www.clinicaltrials.gov/ct2/show/NCT01126346

    Google Scholar 

  36. Fagotti A, Paris I, Grimolizzi F et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113:335–340

    Article  CAS  PubMed  Google Scholar 

  37. Fagotti A, Costantini B, Vizzielli G et al (2011) HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 122:221–225

    Article  PubMed  Google Scholar 

  38. Fagotti A, Costantini B, Petrillo M et al (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol 127:502–505

    Article  PubMed  Google Scholar 

  39. http://www.clinicaltrials.gov/ct2/show/NCT01539785

    Google Scholar 

  40. http://www.clinicaltrials.gov/ct2/show/NCT01387399

    Google Scholar 

  41. http://www.clinicaltrials.gov/ct2/show/NCT01376752

    Google Scholar 

  42. http://www.clinicaltrials.gov/ct2/show/NCT00426257

    Google Scholar 

  43. http://www.clinicaltrials.gov/ct2/show/NCT01767675

    Google Scholar 

  44. http://www.clinicaltrials.gov/ct2/show/NCT01659554

    Google Scholar 

  45. http://www.clinicaltrials.gov/ct2/show/NCT01970722

    Google Scholar 

  46. http://www.clinicaltrials.gov/ct2/show/NCT00565851

    Google Scholar 

  47. Goere D, Gras-Chaput N, Auperin A et al (2014) Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 14:148

    Article  PubMed Central  PubMed  Google Scholar 

  48. Saada E, Follana P, Peyarde F et al (2011) Pathogenesis and management of refractory malignant ascites. Bull Cancer 98:697–687

    Google Scholar 

  49. Ledermann JA, Raja FA, Fotopoulou C et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Gluidelines for diagnosis, treatment and followup. Ann Oncol 24:vi24–vi32

    Article  PubMed  Google Scholar 

  50. http://www.clinicaltrials.gov/ct2/show/NCT02092298

    Google Scholar 

  51. http://www.clinicaltrials.gov/ct2/show/NCT02040142

    Google Scholar 

  52. http://www.clinicaltrials.gov/ct2/show/NCT01342653

    Google Scholar 

  53. http://www.clinicaltrials.gov/ct2/show/NCT01683864

    Google Scholar 

  54. http://www.clinicaltrials.gov/ct2/show/NCT01471132

    Google Scholar 

  55. http://www.clinicaltrials.gov/ct2/show/NCT01815359

    Google Scholar 

  56. http://www.clinicaltrials.gov/ct2/show/NCT01226394

    Google Scholar 

  57. http://www.clinicaltrials.gov/ct2/show/NCT01628211

    Google Scholar 

  58. Fagotti A, Petrillo M, Costantini B et al (2014) Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series. Gynecol Oncol 132:303–306

    Article  CAS  PubMed  Google Scholar 

  59. Gallotta V, Fagotti A, Fanfani F et al (2014) Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc 28:1808–1815

    Article  PubMed  Google Scholar 

  60. Ferron G, Gesson-Paute A, Classe JM, Querleu D (2005) Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol 99:358–361

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Catholic University of Sacred Heart, Rome, Italy

    Barbara Costantini

Authors
  1. Barbara Costantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Fagotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulia Montori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Federico Coccolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luca Ansaloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanni Scambia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara Costantini .

Editor information

Editors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

  2. Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

    Enrico Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Costantini, B., Fagotti, A., Montori, G., Coccolini, F., Ansaloni, L., Scambia, G. (2015). New Trials. In: Di Giorgio, A., Pinto, E. (eds) Treatment of Peritoneal Surface Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5711-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5711-1_25

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5710-4

  • Online ISBN: 978-88-470-5711-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation